Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LXT-101

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Morphology of nanostructures and their long-acting properties in vivo for a novel synthetic peptide of gonadotropin-releasing hormone antagonist.
OBJECTIVES To demonstrate the correlation between the nanostructure formation and the long duration of action in vivo of peptides… Expand
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Oral delivery of oil-based formulation for a novel synthetic cationic peptide of GnRH (gonadotropin-releasing hormone) antagonist for prostate cancer treatment.
LXT-101, a cationic peptide is a novel antagonist of gonadotropin-releasing hormone (GnRH) for prostate cancer treatment. However… Expand
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
2011
2011
Multivesicular liposome (MVL) sustained delivery of a novel synthetic cationic GnRH antagonist for prostate cancer treatment.
OBJECTIVES Multivesicular liposomes (MVLs) are often used as an appropriate carrier for delivering peptides due to high drug… Expand
Is this relevant?
2011
2011
In-vitro/in-vivo studies of the biodegradable poly-(D,L-lactide-co-glycolide) microspheres of a novel luteinizing hormone-releasing hormone antagonist for prostate cancer treatment.
The introduction of luteinizing hormone-releasing hormone (LHRH) analogs and their antagonists is revolutionizing the treatment… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
[Multivesicular liposome sustained delivery of a novel synthetic electropositive Positive GnRH antagonist LXT-101: preparation and in vitro evaluation].
Using a simple method to determine the interaction between peptide and lipid bilayer and then deciding how to modify formulation… Expand
Is this relevant?
2008
2008
[Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs].
This paper developed a sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/MS) method… Expand
Is this relevant?
2006
2006
Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist.
A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2006
2006
In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats
LXT-101 is a newly developed GnRH (gonadotropin-releasing hormone) analogue. In this study, the in vivo pharmacological profile… Expand
Is this relevant?
2005
2005
Biological characterization of a novel and potent gonadotropin releasing hormone （GnRH） antagonist LXT-101
AIM The biological characterization of LXT-101 was investigated in vivo using intact male rats and nude mice bearing xenografts… Expand
Is this relevant?
2004
2004
Pharmacological profile of a new and potent gonadotropin releasing hormone antagonist LXT-101
AIM: To investigate the pharmacological effect of LXT-101 on serum testosterone level in intact male rats. METHODS: Ratswere… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE